Faculty Opinions recommendation of Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival.

2014 ◽  
Author(s):  
Robin Condliffe
Keyword(s):  
Systemic Sclerosis ◽  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Clinical Characteristics ◽  
Term Survival ◽  
Long Term Survival ◽  
Pulmonary Arterial

scholarly journals Screening for pulmonary arterial hypertension in patients with systemic sclerosis: Clinical characteristics at diagnosis and long-term survival

2011 ◽  
Vol 63 (11) ◽  
pp. 3522-3530 ◽  
Author(s):  
Marc Humbert ◽  
Azzedine Yaici ◽  
Pascal de Groote ◽  
David Montani ◽  
Olivier Sitbon ◽  
...  
Keyword(s):  
Systemic Sclerosis ◽  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Clinical Characteristics ◽  
Term Survival ◽  
Long Term Survival ◽  
Pulmonary Arterial

Pulmonary Arterial Hypertension in the Elderly-Clinical Characteristics and Long-Term Survival

Lung ◽  
2012 ◽  
Vol 190 (6) ◽  
pp. 645-649 ◽  
Author(s):  
Avi Shimony ◽  
Benjamin D. Fox ◽  
Jonathan Afilalo ◽  
Lawrence G. Rudski ◽  
Andrew Hirsch ◽  
...  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Clinical Characteristics ◽  
The Elderly ◽  
Term Survival ◽  
Long Term Survival ◽  
Pulmonary Arterial

scholarly journals Lower plasma melatonin levels predict worse long-term survival in pulmonary arterial hypertension

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
Z Cai ◽  
T Klein ◽  
L.W Geenen ◽  
L Tu ◽  
S Tian ◽  
...  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Funding Source ◽  
Cardiovascular Research ◽  
Term Survival ◽  
Long Term Survival ◽  
Treatment Naïve ◽  
Pulmonary Arterial ◽  
Endogenous Melatonin

Abstract Background Exogenous melatonin has been reported to be beneficial in the treatment of pulmonary hypertension (PH) in animal models. Multiple mechanisms may be involved, with melatonin exerting anti-oxidant and anti-inflammatory effects, as well as inducing vasodilation and cardio-protection. However, endogenous levels of melatonin in treatment-naïve pulmonary arterial hypertension (PAH) patients and their clinical significance are still unknown. Methods and results Plasma levels of endogenous melatonin were measured by liquid chromatography-tandem mass spectrometry in treatment-naïve PAH patients (n=43) and healthy controls (n=111). Melatonin levels were higher in PAH patients when compared with controls (Median 118.9 [IQR 109.3–147.7] versus 108.0 [102.3–115.2] pM, P<0.001) (Figure 1A). The overall mortality was 26% (11/43) during a median long-term follow-up of 42 [IQR: 32–58] months. When PAH patients were stratified into 4 groups according to the quartiles of melatonin levels, the mortality from below 1st quartile to above 4th quartile was 55% (6/11), 10% (1/10), 0% (0/12), and 40% (4/10), respectively (Figure 1B). Kaplan-Meier analysis further showed that patients with melatonin levels below the 1st quartile (<109.3 pM) had a worse long-term survival than patients with melatonin levels above the 1st quartile (Mean survival times were 46 [95% CI: 30–65] versus 68 [58–77] months, Log-rank, p=0.026) (Figure 1C). Conclusion Endogenous melatonin levels were increased in treatment-naïve PAH patients, and lower levels of melatonin were associated with worse long-term survival in patient with PAH, however, whether exogenous melatonin supplements may be effective as a therapeutic strategy in human PAH remains to be established. Figure 1 Funding Acknowledgement Type of funding source: Foundation. Main funding source(s): This work was supported by the China Scholarship Council (201606230252) as well as the Netherlands CardioVascular Research Initiative: an initiative with support of the Dutch Heart Foundation (CVON2014-11, RECONNECT), and German Center for Cardiovascular Research (DZHK81Z0600207). Instrumentation support was received from AB Sciex, ltd. for LC-MS/MS analyses performed in this study.

scholarly journals Long-term survival comparison in patients with primary and secondary pulmonary arterial hypertension treated with chronic epoprostenol therapy

2003 ◽  
Vol 41 (6) ◽  
pp. 258
Author(s):  
Maninder S. Bedi ◽  
Jessica Spates-Panyon ◽  
Michael M. Mathier ◽  
Ajoy Kapoor ◽  
Guy A. MacGowan ◽  
...  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Term Survival ◽  
Long Term Survival ◽  
Pulmonary Arterial

scholarly journals Long-Term Survival in Idiopathic Pulmonary Arterial Hypertension Associated with Massive Pulmonary Artery Dilation

2011 ◽  
Vol 18 (3) ◽  
pp. e50-e51 ◽  
Author(s):  
Vanja Petrovic ◽  
Christopher J Ryerson ◽  
Robert D Levy
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Present Report ◽  
Pulmonary Arteries ◽  
Idiopathic Pulmonary Arterial Hypertension ◽  
Channel Blockers ◽  
Term Survival ◽  
Long Term Survival ◽  
Pulmonary Arterial

The present report describes two patients with long-term survival after being diagnosed with idiopathic pulmonary arterial hypertension more than 20 years earlier. Both patients were treated with calcium channel blockers for several years and are currently maintained on bosentan, an oral endothelin receptor antagonist. Severe dilation of the main pulmonary arteries is present in both patients and may be related to long-term survival with idiopathic pulmonary arterial hypertension.

von Willebrand Factor Independently Predicts Long-term Survival in Patients With Pulmonary Arterial Hypertension

CHEST Journal ◽  
2005 ◽  
Vol 128 (4) ◽  
pp. 2355-2362 ◽  
Author(s):  
Steven M. Kawut ◽  
Evelyn M. Horn ◽  
Ketevan K. Berekashvili ◽  
Allison C. Widlitz ◽  
Erika B. Rosenzweig ◽  
...  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Von Willebrand Factor ◽  
Term Survival ◽  
Long Term Survival ◽  
Pulmonary Arterial ◽  
Von Willebrand ◽  
Willebrand Factor

An Evaluation of Long-term Survival From Time of Diagnosis in Pulmonary Arterial Hypertension From the REVEAL Registry

CHEST Journal ◽  
2012 ◽  
Vol 142 (2) ◽  
pp. 448-456 ◽  
Author(s):  
Raymond L. Benza ◽  
Dave P. Miller ◽  
Robyn J. Barst ◽  
David B. Badesch ◽  
Adaani E. Frost ◽  
...  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Term Survival ◽  
Long Term Survival ◽  
Pulmonary Arterial
Sign in / Sign up

Export Citation Format

Share Document